On October 23, 2019, Ryan Lynch, the Corporate Controller and Principal Accounting Officer of Concert Pharmaceuticals, Inc. (the “Company”), provided notice of his resignation, effective as of November 27, 2019. Mr. Lynch is leaving the Company to pursue another opportunity and is not departing due to any disagreements with the Company regarding its financial statements or practices. Mr. Lynch will continue to consult for the Company for a period of time.

In connection with Mr. Lynch’s resignation, on November 27, 2019, Marc A. Becker, the Company’s Chief Financial Officer and Principal Financial Officer, will also become the Company’s Principal Accounting Officer.

Mr. Becker, age 47, has served as the Company’s Chief Financial Officer and Principal Financial Officer since January 2018. Prior to joining the Company, Mr. Becker served as the Chief Financial Officer of CRISPR Therapeutics AG, a publicly traded biotechnology company, from February 2016 to September 2017. From January 2012 to February 2016, Mr. Becker was the Chief Financial Officer of rEVO Biologics, Inc., a biotechnology company. Prior to rEVO Biologics, Mr. Becker held roles of increasing responsibility at Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A., from August 2001 to October 2011, culminating in Vice President, Finance. Mr. Becker received an M.B.A. from Babson College and a B.S. in Business Administration from the University of Massachusetts and was licensed as a certified public accountant.

There is no family relationship between Mr. Becker and any of the Company’s directors or executive officers.

About Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)

Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company’s product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.